GSK will report its Q3 results on October 28, facing a $2.2 billion charge from a Zantac legal settlement that ends years of uncertainty. Despite setbacks like a failed cough program and increased debt from acquisitions, the company is relying on strong growth in specialty medicines, especially HIV treatments like Cabenuva and Apretude, to offset challenges. The launch of Exdensur and progress in vaccines will be key to watch, as management aims for over £40 billion in sales by 2031. The report will reveal if specialty medicines can sustain growth amid patent expirations and legal costs.
As GSK prepares to report its Q3 results on October 28, the market is watching closely how the company will handle its $2.2 billion legal charge and R&D setbacks. On Pluang, GSK shares trade at USD 50.75, down 0.90% as of October 24, 2026, 22:21 WIB, with a market cap of $101.72 billion. Investor interest remains strong with 100% buy orders and a dividend yield of 3.58%, reflecting confidence in the company’s long-term prospects despite current challenges.
GSK's hepatitis B treatment, Hibsago (bepirovirsen), received FDA approval for adults with chronic hepatitis B without cirrhosis, supporting Jefferies' forecast of peak annual sales at £2.2 billion. The drug offers a potential functional cure, allowi...
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
